Alternative Acts: Oncogenic Splicing of Steroidogenic Enzymes in Prostate Cancer.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 30530817.
- Also identified by DOI 10.1158/1078-0432.CCR-18-3410 and PMC identifier 6377826.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Castration-resistant prostate cancer is characterized by loss of the androgen inactivation enzyme HSD17B2, emphasizing the importance of intratumoral androgens in tumor progression. Inactive isoforms generated by alternative splicing destabilize the wild-type enzyme, adding steroidogenesis to other prostate cancer drivers that undergo oncogenic splicing, highlighting aberrant splicing as a therapeutic target.See related article by Gao et al., p. 1291.
Medical subject headings
- Prostatic Neoplasms
- Receptors, Androgen